论文部分内容阅读
目的建立体外筛选分析的方法来确定临床所用治疗阿尔茨海默病、帕金森综合症以及骨质疏松症的中药中哪种中药以及哪些成分是与铁离子(Fe3+)络合的主要成分,并评估其络合强度。方法基于Fe3+对螺环罗丹明B酰肼衍生物开环显色反应的催化作用,建立了催化光度法测定中药煎液中游离态Fe3+的方法,进而通过加入一定量Fe3+测定被络合的程度来评估中药成分与铁络合的强度。结果补肾中药对Fe3+的络合率较高;采用催化光度法测定中药煎液中游离Fe3+的量,线性范围1.68~22.4 mg/L,r=0.999 0;平均加标回收率在90.45%~104.11%,RSD<5%。结论该方法可应用于评估中药络合游离Fe3+强度。
OBJECTIVE: To establish an in vitro screening assay to determine which traditional Chinese medicine (TCM) used in the clinical treatment of Alzheimer’s disease, Parkinson’s disease and osteoporosis and which components are the main components of complexing with ferric ion (Fe3 +). Assess its complex strength. Methods Based on the catalytic effect of Fe3 + on the ring-opening color reaction of spiro rhodamine B hydrazide derivatives, a method of catalytic spectrophotometry for the determination of free Fe3 + in decoctions of traditional Chinese medicine was established, and the degree of complexation was determined by adding a certain amount of Fe3 + Assess the strength of Chinese medicine composition and iron complexation. Results The ratio of Fe3 + in Bushen Chinese medicine was high. The amount of free Fe3 + in Chinese herbal decoction was determined by catalytic spectrophotometry with the linear range of 1.68 ~ 22.4 mg / L, r = 0.999 0. The average recovery was 90.45% -104.11 %, RSD <5%. Conclusion This method can be applied to evaluate the complexation of traditional Chinese medicine free Fe3 +.